ClinicalTrials.Veeva

Menu

Thromboelastography (TEG) and Clopidogrel Withdrawal Time in Elderly Patients With Hip Fracture

Zhejiang University logo

Zhejiang University

Status

Unknown

Conditions

Hip Fracture

Treatments

Procedure: Thrombelastograph and surgical timing

Study type

Interventional

Funder types

Other

Identifiers

NCT04165538
2019-324

Details and patient eligibility

About

In the elderly patients with hip fracture, some often take antiplatelet drugs such as clopidogrel due to the ischemic cardiovascular or cerebrovascular diseases. In traditional practice, these patients often need to stop medication for 5-7 days before surgery. But on the other hand, delayed surgery will lead to a significant increase in fracture related complications. Therefore, the appropriate time for drug withdrawal is particularly important in this population.

Thromboelastography is a monitoring method that can accurately judge the anticoagulation status of patients. We hope to use thromboelastography to guide the time of drug withdrawal, shorten the time of drug withdrawal as much as possible, and reduce the incidence of fracture related complications without increasing the risk of massive hemorrhage.

Enrollment

140 estimated patients

Sex

All

Ages

60+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • hip fracture and operation
  • taking clopidogrel for more than one week before injury, with or without taking aspirin at the same time

Exclusion criteria

  • high energy injury (such as traffic accident, falling from height), bilateral hip fracture, multiple fractures or injuries, pathological fracture
  • malignant tumor patients
  • hormone users
  • patients with recent active bleeding or bleeding ulcer
  • primary or secondary coagulation dysfunction or depression caused by other reasons than taking antiplatelet drugs (for example, taking warfarin)
  • patients with other acute or unstable diseases requiring delayed surgery (acute heart failure, myocardial infarction, cerebral infarction, cerebral hemorrhage, severe pulmonary infection, deep vein thrombosis or pulmonary embolism, etc.)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

140 participants in 2 patient groups

TEG group
Experimental group
Treatment:
Procedure: Thrombelastograph and surgical timing
Non-TEG group
No Intervention group

Trial contacts and locations

0

Loading...

Central trial contact

Min Yan, Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems